%	O
%	O
TITLE	O

HPV	O
-	O
driven	O
oropharyngeal	O
squamous	O
cell	O
cancer	O
in	O
Croatia	B-Study_Location
-	O
Demography	O
and	O
survival	O
.	O

%	O
%	O
ABSTRACT	O

Head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
HNSCC	O
)	O
is	O
the	O
sixth	O
most	O
common	O
malignancy	O
worldwide	O
.	O

Main	O
HNSCC	O
risk	O
factors	O
are	O
tobacco	O
,	O
alcohol	O
,	O
and	O
high	O
-	O
risk	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
.	O

HPV	O
+	O
oropharyngeal	O
squamous	O
cell	O
cancer	O
(	O
OPSCC	O
)	O
usually	O
have	O
different	O
etiology	O
,	O
increasing	O
incidence	B-Incidence_or_Prevalence
and	O
often	O
show	O
an	O
improved	O
survival	O
when	O
compared	O
to	O
HPV	O
-	O
negative	O
cases	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
retrospectively	O
examine	O
the	O
influence	O
of	O
HPV	O
on	O
the	O
survival	O
of	O
OPSCC	O
patients	O
in	O
a	O
non	O
-	O
Western	O
population	O
setting	O
.	O
We	O
determined	O
the	O
presence	O
of	O
HPV	O
DNA	O
and	O
/	O
or	O
RNA	O
in	O
99	B-Study_Cohort
formalin	I-Study_Cohort
-	I-Study_Cohort
fixed	I-Study_Cohort
paraffin	I-Study_Cohort
embedded	I-Study_Cohort
(	I-Study_Cohort
FFPE	I-Study_Cohort
)	I-Study_Cohort
tissue	I-Study_Cohort
samples	I-Study_Cohort
of	I-Study_Cohort
OPSCC	I-Study_Cohort
patients	I-Study_Cohort
treated	O
between	O
2002	B-Study_Time
and	I-Study_Time
2015	I-Study_Time
.	I-Study_Time

Patients	O
were	O
compared	O
based	O
on	O
laboratory	O
,	O
demographic	O
,	O
clinical	O
,	O
life	O
style	O
characteristics	O
and	O
survival	O
.	O
HPV	O
RNA	O
was	O
found	O
in	O
29	O
.	O
3	O
%	O
cases	O
.	O

However	O
,	O
groups	O
based	O
on	O
HPV	O
data	O
(	O
either	O
RNA	O
,	O
DNA	O
or	O
retrospectively	O
collected	O
p16	O
staining	O
)	O
did	O
not	O
show	O
significant	O
differences	O
.	O

Overall	O
,	O
5	O
-	O
year	O
survival	O
was	O
30	O
%	O
with	O
minimal	O
influence	O
of	O
the	O
HPV	O
positivity	O
.	O

The	O
HPV	O
influence	O
on	O
survival	O
of	O
OPSCC	O
patients	O
is	O
not	O
identical	O
between	O
populations	O
probably	O
due	O
to	O
other	O
factors	O
overshadowing	O
the	O
HPV	O
effect	O
.	O

This	O
should	O
be	O
taken	O
into	O
account	O
when	O
treatment	O
or	O
policy	O
decisions	O
are	O
made	O
in	O
each	O
particular	O
setting	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

We	O
determined	O
the	O
presence	O
of	O
HPV	O
DNA	O
and	O
/	O
or	O
RNA	O
in	O
99	B-Study_Cohort
formalin	I-Study_Cohort
-	I-Study_Cohort
fixed	I-Study_Cohort
paraffin	I-Study_Cohort
embed	I-Study_Cohort
-	I-Study_Cohort
ded	I-Study_Cohort
(	I-Study_Cohort
FFPE	I-Study_Cohort
)	I-Study_Cohort
tissue	I-Study_Cohort
samples	I-Study_Cohort
of	I-Study_Cohort
OPSCC	I-Study_Cohort
patients	I-Study_Cohort
treated	O
between	O
2002	B-Study_Time
and	I-Study_Time
2015	I-Study_Time
.	O

Patients	O
were	O
compared	O
based	O
on	O
laboratory	O
,	O
demographic	O
,	O
clinical	O
,	O
life	O
style	O
characteristics	O
and	O
survival	O
.	O

For	O
this	O
study	O
,	O
we	O
collected	O
a	O
subset	O
of	O
available	O
FFPE	O
tumor	O
tissue	B-HPV_Sample_Type
from	O
104	O
OPSCC	O
patients	O
treated	O
at	O
the	O
University	O
Hospital	O
Center	O
Zagreb	O
between	O
2002	B-Study_Time
and	I-Study_Time
2015	I-Study_Time
.	I-Study_Time

According	O
to	O
the	O

International	O
Classification	O
of	O
Disease	O
(	O
ICD	O
-	O
10	O
)	O
,	O
tumors	O
included	O
tonsils	O
(	O
C09	O
)	O
,	O
base	O
of	O
tongue	O
(	O
C01	O
)	O
,	O
soft	O
palate	O
(	O
C05	O
.	O
1	O
)	O
,	O
lateral	O
wall	O
(	O
C10	O
.	O
2	O
)	O
and	O
posterior	O
wall	O
of	O
oropharynx	O
(	O
C10	O
.	O
3	O
)	O
.	O

One	O
patient	O
had	O
unspecified	O
oropharynx	O
tumor	O
localization	O
.	O

Upon	O
medical	O
records	O
reexamination	O
,	O
five	O
cases	O
were	O
excluded	O
as	O
the	O
tumor	O
originated	O
from	O
supraglotis	O
/	O
hypopharynx	O
,	O
thus	O
99	O
cases	O
were	O
retained	O
for	O
analysis	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Bioethical	O
Board	O
of	O
the	O
Ruđer	O
Boˇs	O
-	O
ković	O
Institute	O
(	O
BEP	O
-	O
3748	O
/	O
2	O
-	O
2014	O
)	O
and	O
the	O
Ethical	O
Board	O
of	O
the	O
University	O
Hospital	O
Center	O
Zagreb	O
(	O
8	O
.	O
1	O
-	O
14	O
/	O
47	O
-	O
2	O
,	O
02	O
/	O
21	O
-	O
JG	O
)	O
.	O

Since	O
the	O
study	B-Study_Type
was	I-Study_Type
retrospective	I-Study_Type
and	O
performed	O
on	O
anon	O
-	O
ymized	O
data	O
from	O
often	O
deceased	O
patients	O
,	O
the	O
Ethical	O
boards	O
waived	O
the	O
necessity	O
of	O
obtaining	O
additional	O
informed	O
consent	O
.	O

Medical	O
records	O
and	O
patient’s	O
vital	O
status	O
,	O
including	O
previous	O
p16	O
staining	O
where	O
available	O
,	O
were	O
obtained	O
from	O
the	O
hospital	O
information	O
system	O
and	O
the	O
Croatian	O
National	O
Cancer	O
Registry	O
[	O
]	O
and	O
contained	O
relevant	O
data	O
collected	O
during	O
the	O
establishment	O
of	O
the	O
initial	O
diagnosis	O
including	O
pathological	O
assessment	O
.	O

Original	O
patient	O
management	O
treat	O
-	O
ment	O
decisions	O
were	O
not	O
based	O
upon	O
HPV	O
DNA	O
or	O
RNA	O
testing	O
but	O
were	O
made	O
according	O
to	O
tumor	O
stage	O
and	O
overall	O
patient	O
state	O
.	O

Data	O
from	O
the	O
National	O
Cancer	O
Registry	O
indicates	O
that	O
in	O
the	O
same	O
period	O
there	O
were	O
approximately	O
1600	O
OPSCC	O
patients	O
diagnosed	O
throughout	O
Croatia	B-Study_Location
with	O
the	O
same	O
diagnosis	O
codes	O
as	O
used	O
in	O
the	O
manuscript	O
.	O

However	O
,	O
of	O
this	O
number	O
almost	O
500	O
were	O
reported	O
to	O
the	O
Registry	O
as	O
C10	O
.	O
9	O
oropharynx	O
,	O
unspecified	O
,	O
which	O
are	O
underrepresented	O
in	O
our	O
analyzed	O
tis	O
-	O
sues	O
.	O

The	O
University	O
Hospital	O
Center	O
Zagreb	O
treated	O
403	O
oropharyngeal	O
cancer	O
patients	O
during	O
this	O
period	O
.	O

Thus	O
,	O
our	O
sample	O
represents	O
approximately	O
7	O
%	O
of	O
cancer	O
patients	O
in	O
Croatia	O
and	O
approximately	O
25	O
%	O
of	O
patients	O
treated	O
at	O
the	O
hospital	O
.	O

Malignancies	O
were	O
staged	O
according	O
to	O
the	O
7th	O
Edition	O
of	O
the	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
(	O
AJCC	O
)	O
and	O
the	O
Union	O
for	O
International	O
Cancer	O
Control	O
(	O
UICC	O
)	O
TNM	O
Classification	O
of	O
Malignant	O
tumors	O
[	O
]	O
.	O

The	O
pathologic	O
classification	O
was	O
used	O
and	O
supplemented	O
with	O
the	O
clinical	O
classification	O
if	O
missing	O
.	O

For	O
the	O
survival	O
analyses	O
,	O
both	O
7th	O
and	O
8th	O
AJCC	O
Edition	O
stag	O
-	O
ing	O
guidelines	O
[	O
,	O
]	O
have	O
been	O
used	O
and	O
compared	O
.	O

Patient	O
survival	O
time	O
in	O
months	O
was	O
cal	O
-	O
culated	O
from	O
the	O
date	O
of	O
earliest	O
diagnosis	O
to	O
registered	O
time	O
of	O
death	O
(	O
all	O
cause	O
)	O
or	O
December	O
31st	O
,	O
2017	O
.	O

Nucleic	O
acid	O
isolation	O

Approximately	O
5–7	O
10	O
μm	O
serial	O
sections	B-HPV_Sample_Type
of	O
each	O
tissue	B-HPV_Sample_Type
block	O
were	O
obtained	O
for	O
DNA	O
and	O
another	O
5–7	O
sections	O
for	O
RNA	O
isolation	O
.	O

Precautions	O
were	O
taken	O
to	O
avoid	O
sample	B-HPV_Sample_Type
cross	O
-	O
contam	O
-	O
ination	O
,	O
including	O
change	O
of	O
knife	O
and	O
meticulous	O
cleaning	O
of	O
the	O
microtome	O
for	O
each	O
new	O
block	B-HPV_Sample_Type
as	O
well	O
as	O
discarding	O
top	O
layers	O
of	O
each	O
block	O
that	O
could	O
potentially	O
have	O
been	O
contami	O
-	O
nated	O
during	O
storage	O
.	O

DNA	O
was	O
isolated	O
with	O
a	O
NucleoSpin	O
Tissue	O
kit	O
(	O
Machery	O
-	O
Nagel	O
)	O
,	O
while	O
RNeasy	O
FFPE	O
Kit	O
(	O
Qiagen	O
)	O
was	O
used	O
for	O
total	O
RNA	O
isolation	O
of	O
HPV	O
+	O
samples	B-HPV_Sample_Type
.	O

Isolation	O
proce	O
-	O
dures	O
were	O
performed	O
according	O
to	O
the	O
respective	O
manufacturer’s	O
protocol	O
.	O

Extracted	O
DNA	O
and	O
RNA	O
were	O
quantified	O
using	O
NanoPhotometer	O
(	O
Implen	O
,	O
Germany	O
)	O
.	O

HPV	O
DNA	O
detection	O

Extracted	O
DNA	O
adequacy	O
was	O
further	O
confirmed	O
by	O
PCR	B-HPV_Lab_Technique
amplification	I-HPV_Lab_Technique
of	O
beta	O
-	O
actin	O
gene	O
(	O
~	O
99	O
bp	O
)	O
[	O
]	O
.	O

HPV	O
DNA	O
detection	O
was	O
performed	O
using	O
short	O
primers	O
suitable	O
for	O
FFPE	O
tissue	B-HPV_Sample_Type
anal	O
-	O
ysis	O
,	O
GP5	O
/	O
6	O
(	O
~	O
142bp	O
amplicon	O
)	O
and	O
SPF	O
-	O
10	O
(	O
~	O
65bp	O
amplicon	O
)	O
previously	O
described	O
[	O
,	O
]	O
.	O

CaSki	O
cell	O
line	O
DNA	O
containing	O
HPV	O
-	O
16	O
was	O
used	O
as	O
positive	O
control	O
,	O
while	O
negative	O
control	O
reactions	O
contained	O
all	O
reagents	O
except	O
DNA	O
.	O

All	O
standard	O
precautions	O
for	O
avoiding	O
cross	O
con	O
-	O
tamination	O
were	O
followed	O
and	O
reactions	O
were	O
prepared	O
within	O
a	O
UV	O
decontaminated	O
laminar	O
flow	O
hood	O
.	O

PCR	B-HPV_Lab_Technique
products	O
(	O
10	O
μl	O
)	O
were	O
visualized	O
after	O
3	O
%	O
agarose	O
gel	O
electrophoresis	O
.	O

A	O
sample	B-HPV_Sample_Type
was	O
considered	O
as	O
HPV	O
DNA	O
positive	O
if	O
consensus	O
primers	O
,	O
either	O
GP	O
or	O
SPF	O
directed	O
PCR	B-HPV_Lab_Technique
was	O

positive	O
and	O
the	O
results	O
valid	O
if	O
beta	O
-	O
actin	O
directed	O
PCR	B-HPV_Lab_Technique
(	O
internal	O
control	O
)	O
was	O
successful	O
.	O

HPV	O
specific	O
genotyping	O
was	O
not	O
performed	O
due	O
to	O
DNA	O
degradation	O
in	O
FFPE	O
samples	B-HPV_Sample_Type
.	O

E6	O
/	O
E6�I	O
mRNA	O
expression	O
analyses	O

All	O
HPV	O
DNA	O
positive	O
samples	B-HPV_Sample_Type
were	O
selected	O
for	O
RNA	O
isolation	O
and	O
HPV	O
-	O
16	O
E6	O
mRNA	O
detec	O
-	O
tion	O
.	O

RNAse	O
-	O
free	O
DNAse	O
digestion	O
was	O
performed	O
to	O
further	O
limit	O
DNA	O
contamination	O
.	O

Briefly	O
,	O
1	O
μg	O
of	O
RNA	O
was	O
reverse	O
transcribed	O
using	O
QuantiTect	O
Reverse	O
Transcription	O
kit	O
(	O
Qia	O
-	O
gen	O
)	O
according	O
to	O
the	O
manufacturer’s	O
protocol	O
.	O

Most	O
abundant	O
splice	O
variant	O
of	O
the	O
E6	O
open	O
reading	O
frame	O
(	O
E6�I	O
)	O
was	O
detected	O
by	O
PCR	B-HPV_Lab_Technique
[	O
]	O
and	O
the	O
amplicons	O
(	O
~	O
86	O
bp	O
)	O
visualized	O
by	O
a	O
3	O
%	O
agarose	O
electrophoresis	O
.	O

Suitability	O
of	O
cDNA	O
for	O
amplification	O
was	O
confirmed	O
by	O
beta	O
-	O
actin	O
PCR	B-HPV_Lab_Technique
(	O
~	O
99	O
bp	O
)	O
.	O

CaSki	O
cell	O
line	O
cDNA	O
served	O
as	O
positive	O
control	O
,	O
while	O
negative	O
control	O
con	O
-	O
tained	O
all	O
reagents	O
except	O
cDNA	O
.	O

Immunohistochemistry	B-HPV_Lab_Technique

The	B-HPV_Lab_Technique
p16	I-HPV_Lab_Technique
data	I-HPV_Lab_Technique
was	I-HPV_Lab_Technique
obtained	I-HPV_Lab_Technique
from	I-HPV_Lab_Technique
medical	I-HPV_Lab_Technique
records	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
staining	I-HPV_Lab_Technique
done	I-HPV_Lab_Technique
by	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
CINtec	I-HPV_Lab_Technique
p16INK4a	I-HPV_Lab_Technique
Histology	I-HPV_Lab_Technique
Kit	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
mtm	I-HPV_Lab_Technique
laboratories	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Heidelberg	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Germany	I-HPV_Lab_Technique
)	O
according	O
to	O
the	O
manufacturer	O
instructions	O
[	O
]	O
.	O

The	O
staining	O
was	O
evaluated	O
by	O
the	O
same	O
pathologist	O
(	O
AJ	O
)	O
for	O
all	O
patients	O
.	O

The	O
overexpressed	O
p16	O
(	O
�70	O
%	O
)	O
in	O
tumour	O
cells	O
was	O
considered	O
as	O
positive	O
.	O

Statistical	O
analyses	O

Based	O
on	O
HPV	O
DNA	O
and	O
RNA	O
testing	O
results	O
,	O
samples	B-HPV_Sample_Type
were	O
grouped	O
in	O
three	O
distinct	O
groups	O
:	O
HPV	O
DNA	O
/	O
RNA	O
negative	O
)	O
,	O
HPV	O
DNA	O
positive	O
and	O
HPV	O
RNA	O
positive	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
R	O
(	O
v3	O
.	O
4	O
.	O
2	O
)	O
and	O
MedCalc	O
(	O
v11	O
.	O
4	O
MedCalc	O
Software	O
,	O
Ostend	O
,	O
Belgium	O
)	O
.	O

Patient’s	O
characteristics	O
for	O
specific	O
variables	O
(	O
including	O
gender	O
,	O
tumor	O
localization	O
,	O
grade	O
,	O
TNM	O
and	O
therapy	O
)	O
were	O
compared	O
between	O
the	O
groups	O
using	O
Test	O
of	O
Independence	O
/	O
Chi	O
-	O
Square	O
and	O
correlation	O
.	O

Age	O
at	O
diagnosis	O
was	O
analyzed	O
using	O
T	O
-	O
test	O
.	O

For	O
statistical	O
purposes	O
,	O
missing	O
data	O
was	O
recoded	O
as	O
“Unknown”	O
but	O
retained	O
to	O
minimize	O
possible	O
selection	O
bias	O
.	O

Survival	O
data	O
was	O
assessed	O
in	O
MedCalc	O
using	O
Kaplan	O
-	O
Meier	O
analyses	O
from	O
which	O
all	O
non	O
-	O
primary	O
tumors	O
(	O
n	O
=	O
8	O
)	O
and	O
patients	O
with	O
unavailable	O
survival	O
data	O
(	O
n	O
=	O
10	O
)	O
were	O
excluded	O
.	O

When	O
assessing	O
tumor	O
stag	O
-	O
ing	O
,	O
patients	O
were	O
grouped	O
to	O
reduce	O
the	O
number	O
of	O
subgroups	O
:	O
for	O
T	O
classification	O
“1–2”	O
and	O
“2–3”	O
groups	O
were	O
considered	O
.	O

For	O
N	O
classification	O
,	O
“0–1”	O
and	O
“2–3”	O
groups	O
were	O
made	O
,	O
while	O
for	O
tumor	O
stages	O
“I	O
-	O
II”	O
and	O
“III	O
-	O
IV”	O
groups	O
were	O
considered	O
irrespective	O
of	O
staging	O
edition	O
.	O

Patients	O
self	O
-	O
reporting	O
weekly	O
or	O
more	O
common	O
strong	O
spirit	O
use	O
or	O
daily	O
other	O
alcohol	O
use	O
were	O
grouped	O
as	O
heavy	O
drinkers	O
,	O
while	O
patients	O
with	O
self	O
-	O
reported	O
occasional	O
or	O
limited	O
alcohol	O
use	O
were	O
grouped	O
as	O
occasional	O
drinkers	O
.	O

Influence	O
of	O
individual	O
variables	O
on	O
survival	O
were	O
modeled	O
with	O
Cox	O
proportional	O
hazards	O
regression	O
in	O
univariate	O
analysis	O
for	O
age	O
,	O
gender	O
,	O
HPV	O
DNA	O
pos	O
-	O
itivity	O
,	O
HPV	O
RNA	O
positivity	O
,	O
p16	O
positivity	O
,	O
T	O
classification	O
,	O
N	O
classification	O
,	O
stage	O
,	O
grade	O
,	O
smok	O
-	O
ing	O
history	O
and	O
drinking	O
history	O
.	O

Several	O
multivariate	O
Cox	O
proportional	O
hazards	O
regression	O
models	O
were	O
created	O
from	O
selected	O
significant	O
or	O
relevant	O
variables	O
(	O
T	O
/	O
N	O
classification	O
)	O
and	O
HPV	O
groups	O
.	O

Several	O
models	O
were	O
created	O
from	O
all	O
entered	O
variables	O
without	O
removal	O
of	O
non	O
-	O
significant	O
variables	O
to	O
enable	O
the	O
comparison	O
of	O
individual	O
variable	O
effects	O
.	O

However	O
,	O
the	O
mod	O
-	O
els	O
including	O
“Unknown”	O
groups	O
couldn’t	O
be	O
solved	O
so	O
for	O
multivariate	O
analysis	O
,	O
samples	B-HPV_Sample_Type
with	O
“Unknown”	O
factors	O
were	O
removed	O
.	O

P	O
values	O
less	O
than	O
0	O
.	O
05	O
were	O
considered	O
significant	O
.	O

